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Tablet dosage formAbstract A simple, speciﬁc and accurate reverse phase liquid chromatographic method was devel-
oped for the simultaneous determination of Atorvastatin calcium and Nicotinic acid in tablet dos-
age forms. The analysis has been performed by using Agilent ZORBAX SB-C18 (150 · 4.6 mm,
3.5 u) and mobile phase containing acetonitrile: distilled water (85:15) at pH 4.5 (adjusted with
phosphoric acid). The detection was carried out at 261 nm with a ﬂow rate of 1.0 ml/min. The reten-
tion times of Atorvastatin calcium and Nicotinic acid were 6.092 and 3.125 min, respectively. The
method was validated according to ICH guidelines. The method was validated for speciﬁcity, pre-
cision, linearity, accuracy and robustness. The linearity for Atorvastatin calcium and Nicotinic acid
were in the range of 2–12 and 10–80 lg/ml respectively. The recoveries of Atorvastatin calcium and
Nicotinic acid were found to be in the range of 99.031% and 99.744% respectively. The proposed
method was validated and successfully applied to the estimation of Atorvastatin calcium and Nic-
otinic acid in combined tablet formulation.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atorvastatin is chemically (3R,5R)-7-[2-(4-ﬂuorophenyl) -3-
phenyl-4-(phenylcarbamoyl)-5-(propan-2yl)1H-pyrrol-1-yl-3,5-dihydroxyheptanoic acid calcium salt trihydrate Fig. 1
(Gennaro, 2000). Atorvastatin selectively and competitively
inhibits the hepatic enzyme HMG-CoA reductase. Nicotinic
acid is chemically pyridine-3-carboxylic acid Fig. 1 (Gennaro,
2000). Nicotinic acid lowers plasma triglyceride and cholesterol
concentration.
Several studies for the estimation of the drug using various
techniques have been carried out for Atorvastatin and Nico-
tinic acid, some of them being: extractive spectrophotometric
determination of Atorvastatin in bulk and pharmaceutical for-
mulations (Erk, 2003), HPLC assay and pharmaco-kinetic
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Figure 1 Chemical structure of Atorvastatin calcium and Nicotinic acid.
Figure 2 Chromatogram of the placebo.
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of Atorvastatin self-micro emulsifying drug delivery system
(Shen et al., 2006), liquid chromatographic determination
of Atorvastatin in bulk drug, tablets and human plasma
(Altuntas et al., 2004), HPLC method for the determination
of Atorvastatin and its impurities in bulk drugs and tablets
(Erturk et al., 2003), Chromatographic and capillary electro-
phoretic method for the analysis of Nicotinic acid and its
metabolites (Iwaki et al., 2000).Though a number of methods
are reported for estimation of individual drug Atorvastatin
and Nicotinic acid or in combination with other drugs to
our knowledge no HPLC method is available for simultaneous
estimation of Atorvastatin and Nicotinic acid in combined
dosage form. Considering this we have decided to develop a
RP-HPLC method for simultaneous estimation of Atorva-
statin and Nicotinic acid in combined dosage form. Validation
of the developed method has gained signiﬁcance nowadays
(Bouabidi et al., 2010,Rozet et al.; 2011). The objective of
validation of an analytical method is to demonstrate that theprocedure, when correctly applied, produces results that are
ﬁt for purpose. The developed method is validated as per
ICH guidelines (ICH, 2005).2. Experimental
2.1. Chemicals and reagents
Atorvastatin and Nicotinic acid working standards were gener-
ous gifts from Lupin Laboratory Limited Aurangabad and
Aurobindo labs hyderabad, India respectively. Combination
drug products of Atorvastatin and Nicotinic acid (Label claim:
Atorvastatin calcium equivalent to Atorvastatin 10 mg, and
Nicotinic acid 375 mg), TONACT plus (Lupin Ltd., Mumbai,
India), were purchased from a local pharmacy. Acetonitrile,
methanol and water used were of HPLC grade. Orthophospho-
ric acid used was of analytical reagent grade.
Figure 3 Chromatogram of standard preparation of Nicotinic acid (75 lg/ml) and Atorvastatin (2 lg/ml).
Figure 4 Chromatogram of sample preparation of Nicotinic acid (75 lg/ml) and Atorvastatin (2 lg/ml).
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JASCO HPLC LC-2000 Plus series, Pump PU-2080, detector
UV-2075 plus, Browin software with Agilent ZORBAX SB-
C18 (150 · 4.6 mm, 3.5 u) column were used. All weights were
taken on electronic balance (Denver, Germany).
3. Method
3.1. Chromatographic conditions
Chromatographic separation was achieved at 18 C and the
detection was carried at 261 nm at a ﬂow rate of 1 mL/min.Run time was kept at 10 min. Prior to the injection of drug
solution, column was equilibrated for 60 min with the mobile
phase ﬂowing through the system. The injection volume was
20 lL for assay level. The analysis has been performed by
using Agilent ZORBAX SB-C18 (150 · 4.6 mm, 3.5 u) and
the mobile phase containing acetonitrile: distilled water
(85:15) at pH 4.5 (adjusted with phosphoric acid).
3.2. Standard preparation
The standard stock solutions 100 ug/ml of Atorvastatin and
100 lg/ml of Nicotinic acid were prepared separately by dis-
solving working standards in methanol and diluting with the
same solvent. Standard calibration solutions of Atorvastatin
Table 1 Summary of validation parameters for the proposed
method.
Parameters Atorvastatin Nicotinic acid
Retention time (min) 6.092 3.125
Theoretical plates 2777.77 4123.607
Tailing factor 0.9 0.8
Linearity range (lg mL1) 2–12 10–80
Correlation coeﬃcient (r) 0.999 0.999
Accuracy (%) 98.93–101.16% 98.83–101.20%
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and 10–80 ug/ml respectively were prepared by diluting stock
solutions with methanol. A representative chromatogram of
standard preparation is shown in (Fig. 3).
3.3. Sample solution
Twenty tablets were weighed and ﬁnely powdered. Powder
equivalent to Atorvastatin 10 mg and 375 mg Nicotinic acid
was accurately weighed into a 100 ml volumetric ﬂask, 30 ml
of diluents was added and sonicated for 15 min with intermit-
tent shaking, made up to the volume with diluents and mixed.
Filter the solution through 0.45 nylon membrane ﬁlter. Dilute
2 ml of the above solution to 100 ml with diluents. A represen-
tative chromatogram of sample preparation is shown in
(Fig. 4).
4. Analytical method validation
4.1. Speciﬁcity
To assess the method speciﬁcity, tablet powder without Ator-
vastatin and Nicotinic acid was prepared with the same excip-
ients as those in the commercial formulation. For RP-HPLC,
the solution was prepared using the same procedure as for
the analytical sample. Placebo solution was injected into the
HPLC system following test conditions, the chromatogram
was recorded and the responses of the peaks if any measured.
Chromatogram of the placebo has not shown any interference
at the retention time of both Atorvastatin and Nicotinic acid
(Fig. 2).
4.2. Precision
Precision was measured in terms of repeatability of application
and measurement. Repeatability of standard application (Sys-
tem precision), inter day precision study of Atorvastatin and
Nicotinic acid were carried out by estimating the correspond-
ing responses 3 times on the same day and on 3 different days
for 3 different concentrations of Atorvastatin (2, 4, 6 lg/ml)
and Nicotinic acid (10, 20, 30 lg/ml). Repeatability expressesTable 2 Result of precision study.
Concentration (lg/ml) Interday (RSD,%) Repeatability (RSD,%) C
2 1.18 0.15 1
4 0.97 0.40 2
6 0.50 0.80 3the precision under the same operating conditions over a short
interval of time. Repeatability is also termed intra-assay preci-
sion. The repeatability studies were carried out by estimating
the response of three different concentrations of Atorvastatin
(2, 4, 6 lg/ml) and Nicotinic acid (10, 20, 30 lg/ml) for tripli-
cate and results are reported in terms of relative standard devi-
ation (RSD). The precision of the method is satisfactory as %
RSD is not more than 2% (Table 2).
4.3. Calibration and linearity
The linearity of method is obtained by preparation of the cali-
bration curve. The calibration curve for Atorvastatin was ob-
tained by plotting the peak area of Atorvastatin versus
concentration of Atorvastatin over the range of 2–12 lg/ml,
and it was found to be linear with r= 0.999. Similarly, the cal-
ibration curve for Nicotinic acid was obtained over the range of
10–80 lg/ml and was found to be linear with r= 0.999. The
slope and intercept value for calibration curve was found
y= 84879x + 38623 for Nicotinic acid and y= 28352x +
4738 for Atorvastatin.
4.4. Accuracy
The recovery experiments were performed by adding a known
quantity of pure standard drug into the solution of the tablet
powder. The sample was then spiked with standard at levels
80%, 100% and 120% of test concentration. The resulting
spiked sample solutions were assayed in triplicate and the re-
sults were compared with the expected results and expressed
as percentage The recoveries of Atorvastatin and Nicotinic
acid were found to be in the range of 98.93–101.16% and
98.83–101.20%, respectively (Table 1).
4.5. Robustness
Robustness of the method was determined by analyzing stan-
dard solutions at normal operating conditions and by chang-
ing some operating analytical conditions such as ﬂow rate,
pH, and detection wavelength. The conditions with the varia-
tion and the results are presented in Table 3.(see Table 4)
4.6. LOD & LOQ
LOD and LOQ were calculated by using the formula 3.3S.D/S
and 10S.D/S where S.D is the standard deviation of Y-inter-
cept and S is the slope of the calibration curve.
5. Results and discussion
For HPLC method optimization different ratios of methanol
and water were tried but it was found that the peaks gotoncentration (lg/ml) Interday (RSD,%) Repeatability (RSD,%)
0 0.18 0.10
0 0.19 0.08
0 0.12 0.10
Table 4 Assay results of combined dosage using proposed method (mean values of three determinations).
Formulation Labeled amount (mg) Amount obtained (mg) % Recovery
Atorvastatin Nicotinic acid Atorvastatin Nicotinic acid Atorvastatin Nicotinic acid
TONACT plus 10 mg 375 mg 9.90 mg ± 0.08 374.04 mg ± 0.9 99.031%± 0.8% 99.744%± 0.24%
Table 3 Robustness.
Robustness study of Atorvastatin Robustness study of Nicotinic acid
Chromatographic changes Chromatographic changes
Factor Level Assay %Deviation Factor Level Assay %Deviation
Flow rate(ml/min) Flow rate(ml/min)
0.8 0.2 99.06 0.03 0.8 0.2 99.8 0.06
1 0 99.03 0 1 0 99.74 0
1.2 0.2 99.01 0.02 1.2 0.2 99.69 0.05
% Deviation at ﬂow rate 0.8 ml is 0.03 and at 1.2 ml is 0.02%
respectively
% Deviation at ﬂow rate 0.8 ml is 0.06 and at 1.2 ml is 0.05%
respectively
pH pH
4.3 0.2 98.99 0.04 4.3 0.2 99.6 0.14
4.5 0 99.03 0 4.5 0 99.74 0
4.7 0.2 99.05 0.02 4.7 0.2 99.84 0.1
%Deviation at pH 4.3 is 0.04 and at 4.7 is 0.02% respectively %Deviation at pH 4.3 is 0.14 and at 4.7 is 0.10% respectively
Wavelength(nm) Wavelength(nm)
256 5 99.08 0.05 256 5 99.82 0.08
261 0 99.03 0 261 0 99.74 0
266 5 98.97 0.06 266 5 99.55 0.19
% Deviation at Wavelength 256 is 0.05 and at 266 is 0.06%
respectively
% Deviation at Wavelength 256 is 0.08 and at 266 is 0.19%
respectively
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placed with acetonitrile. Different ratios of acetonitrile and
water were tried. It was found that acetonitrile: water in the ra-
tio 85:15 v/v at pH 4.5 adjusted with phosphoric acid at a ﬂow
rate 1.0 mL/min gave good peaks. Hence a different combina-
tion of mobile phases and chromatographic conditions was tried
acetonitrile: distilled water (85:15) at pH 4.5 adjusted with phos-
phoric acid as the mobile phase, Agilent ZORBAX SB-C18
(150 · 4.6 mm, 3.5 u) column, 1 mL/min ﬂow rate, 20 lL injec-
tion volume, 18 C column oven temperature, 261 nm wave-
length was found to be suitable for combination. These
chromatographic conditions gave a retention time of 6.092
and 3.125 min for Atorvastatin and Nicotinic acid respectively.
Speciﬁcity of the method was checked by injecting the pla-
cebo solution, no peaks were found at the retention time of
Atorvastatin and Nicotinic acid. The stability of the sample
solution was evaluated by preparing a sample solution as per
the proposed method and analyzed initially and at 1 h time
intervals up to 24 h by keeping the sample solution at room
temperature. A good linear relationship as indicated by corre-
lation coefﬁcient value 0.999 was observed for Atorvastatin
over the range of 2–12 lg/ml and over the range of 10–
80 lg/ml for Nicotinic acid correlation coefﬁcient of 0.999.
Intermediate precision was done by changing the analyst, col-
umn, chemical make with the same chromatographic condi-
tions and the obtained results were within the limits. The
robustness of the method was evaluated by deliberately vary-
ing the chromatographic conditions of the method such as,
ﬂow rate, pH and wavelength. The parameters like tailing fac-tor and retention times showed adherence to the limits. The
accuracy of the method was determined by recovery studies
and the percentage recovery was calculated. The recoveries
of Atorvastatin and Nicotinic acid were found to be in the
range of 98.93–101.16% and 98.83–101.20%, respectively.
The proposed liquid chromatographic method was applied to
the determination of Atorvastatin and Nicotinic acid in their
combined dosage forms (Tablet Tonact plus). The results for
Atorvastatin and Nicotinic acid were comparable with the cor-
responding labeled amounts (Table 6).
6. Conclusion
The HPLC method developed for the analysis of mixture of
Atorvastatin and Nicotinic acid in their pharmaceutical prep-
arations is precise, accurate and with a short run time. The
method was fully validated showing satisfactory data for all
the method validation parameters tested. The developed meth-
od can be conveniently used by the quality control department
to determine the assay of pharmaceutical preparations.Acknowledgements
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